The following article is from Sohu.com and was written by GT.PR.NEWS, translated by ChatGPT. All rights belong to their respective owners.
Shanghai Immunocan Biotech Co., as an innovative biopharmaceutical company, aims to create an antibody drug platform using gene editing technology to assist in biopharmaceutical research and the development of new targeted drugs.
Its gene editing technology significantly improves the efficiency and success rate of producing fully human antibodies in animals by replacing genes in multiple species, enabling the replacement of DNA fragments of single-digit to multi-Mb in a short time without species limitation. This breakthrough technology has significant implications for developing fully humanized antibody drugs targeting tumors and neurological diseases, and has the potential to make great contributions in the field of biopharmaceutical development and benefit society.
Dr. Zhang Jiwei of Shanghai Immunocan Biotech Co. said, “Because we are building a fully humanized mouse platform, based on our mouse platform, we can obtain a fully human antibody sequence after immunization, which greatly shortens the previous process of antibody drug development, thus improving drug efficacy. This provides a better platform for domestic antibody drug development companies to discover their pipeline.”
Dr. Zhao Yingjun of Shanghai Immunocan Biotech Co. stated that using their antibody in drug development eliminates the need for further humanization modification, thus saving time in research and development. Secondly, the fully humanized antibody discovered by their team involves the one-time replacement of the entire length of the variable region of the light chain gene locus in mouse. This complete replacement increases diversity, enabling more high-affinity advantageous antibodies to be discovered in a timely manner.
Immunocan aims to build a professional biotechnology platform and biopharmaceutical research and development base, and to become a hardcore new drug research and development platform, thus promoting the development of the entire industry.
